It’s a good day to be an Sigilon Therapeutics Inc. (SGTX) shareholder

In the latest session, Sigilon Therapeutics Inc. (NASDAQ: SGTX) closed at $0.70 down -5.31% from its previous closing price of $0.74. In other words, the price has decreased by -$0.0393 from its previous closing price. On the day, 557467 shares were traded. SGTX stock price reached its highest trading level at $0.8085 during the session, while it also had its lowest trading level at $0.6900.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.



For a deeper understanding of Sigilon Therapeutics Inc.’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.60 and its Current Ratio is at 2.60. In the meantime, Its Debt-to-Equity ratio is 0.46 whereas as Long-Term Debt/Eq ratio is at 0.31.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Jefferies on November 30, 2021, Downgraded its rating to Hold and sets its target price to $4 from $15 previously.

On October 29, 2021, BTIG Research started tracking the stock assigning a Buy rating and target price of $14.

Valuation Measures:

For the stock, the TTM Price-to-Sale (P/S) ratio is 1.57 while its Price-to-Book (P/B) ratio in mrq is 0.51.

Stock Price History:

Over the past 52 weeks, SGTX has reached a high of $2.09, while it has fallen to a 52-week low of $0.29. The 50-Day Moving Average of the stock is 0.4022, while the 200-Day Moving Average is calculated to be 0.6963.

Shares Statistics:

For the past three months, SGTX has traded an average of 227.14K shares per day and 1.14M over the past ten days. A total of 32.40M shares are outstanding, with a floating share count of 28.13M. Insiders hold about 13.34% of the company’s shares, while institutions hold 52.20% stake in the company. Shares short for SGTX as of Oct 13, 2022 were 126.23k with a Short Ratio of 0.16M, compared to 148.21k on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 0.39% and a Short% of Float of 0.57%.

Earnings Estimates

There are 4 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$0.42 for the current quarter, with a high estimate of -$0.41 and a low estimate of -$0.44, while EPS last year was -$0.63. The consensus estimate for the next quarter is -$0.45, with high estimates of -$0.4 and low estimates of -$0.51.

Analysts are recommending an EPS of between -$1.68 and -$1.77 for the fiscal current year, implying an average EPS of -$1.73. EPS for the following year is -$1.37, with 4 analysts recommending between -$0.73 and -$1.73.

Revenue Estimates

A total of 2 analysts believe the company’s revenue will be $2.5M this quarter.It ranges from a high estimate of $3M to a low estimate of $2M. As of the current estimate, Sigilon Therapeutics Inc.’s year-ago sales were $2.9M, an estimated decrease of -13.80% from the year-ago figure. For the next quarter, 2 analysts are estimating revenue of $2.5M, an increase of 25.60% over than the figure of -$13.80% in the same quarter last year. There is a high estimate of $3M for the next quarter, whereas the lowest estimate is $2M.

A total of 4 analysts have provided revenue estimates for SGTX’s current fiscal year. The highest revenue estimate was $12M, while the lowest revenue estimate was $10M, resulting in an average revenue estimate of $11.5M. In the same quarter a year ago, actual revenue was $9.6M, up 19.80% from the average estimate. Based on 4 analysts’ estimates, the company’s revenue will be $11M in the next fiscal year. The high estimate is $14M and the low estimate is $8M. The average revenue growth estimate for next year is down -4.30% from the average revenue estimate for this year.